Lisa Bollinger, MD

Lisa Bollinger, M.D., is the Chief Medical Officer for Polaryx Therapeutics, a clinical stage biotech and on the Board of Directors for Apogee Therapeutics. Dr. Bollinger’s major areas of focus include, but are not limited to: Pediatric drug development, rare disease drug development, general medicine drug development (Cardiovascular, immunology, metabolic, nephrology, neurology, bone, pulmonary, dermatology). Dr. Bollinger also has experience in pediatric oncology, FDA Advisory Committee Meetings, biosimilars, regulatory inspections, and business development (due diligence). Dr. Bollinger is a pediatrician with 20 years of practice experience who began regulatory work at the US Food and Drug Administration (US FDA) in the Division of Dermatologic and Dental Drug Products. During this time, Dr. Bollinger continued to deliver primary care at Walter Reed Military Medical Center in Bethesda Maryland. She was in senior leadership at the FDA where she led pediatric drug development – establishing policies and then implementing them across both the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). After the FDA, Dr. Bollinger spent time at Amgen (Regulatory Affairs, Regulatory CMC, Pharmacovigilance), and 3 years at Merck (Regulatory Affairs), working cross functionally to bring important therapies to patients. Dr. Bollinger provided consultation for many companies before deciding to join Polaryx Therapeutics as the Chief Medical Officer. She also serves on the Board of Directors for Apogee Therapeutics and advisor for several other companies. With a broad background across both government and private industry, Dr. Bollinger has experience with high level strategy as well as the hands-on work needed for regulatory interactions and provides insights that comes from working at the FDA, and in industry across different aspects of drug development.